185 related articles for article (PubMed ID: 38216668)
1. Advancing cancer immunotherapy: from innovative preclinical models to clinical insights.
Craig AW; Frieboes HB; Videira PA
Sci Rep; 2024 Jan; 14(1):1205. PubMed ID: 38216668
[TBL] [Abstract][Full Text] [Related]
2. The importance of comparative oncology in translational medicine.
Riccardo F; Aurisicchio L; Impellizeri JA; Cavallo F
Cancer Immunol Immunother; 2015 Feb; 64(2):137-48. PubMed ID: 25548094
[TBL] [Abstract][Full Text] [Related]
3. From cell regulation to patient survival: 2nd Cancer Immunotherapy and Immunomonitoring (CITIM) meeting, Budapest, 2-5 May 2011.
Umansky V; Malyguine A; Kotlan B; Aptsiauri N; Shurin MR
Cancer Immunol Immunother; 2012 Feb; 61(2):295-301. PubMed ID: 21953053
[No Abstract] [Full Text] [Related]
4. From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma.
Anker J; Miller J; Taylor N; Kyprianou N; Tsao CK
Cells; 2021 Nov; 10(11):. PubMed ID: 34831452
[TBL] [Abstract][Full Text] [Related]
5. Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans.
Oh W; Kim AMJ; Dhawan D; Kirkham PM; Ostafe R; Franco J; Aryal UK; Carnahan RH; Patsekin V; Robinson JP; Knapp DW; Lim SO
Cancer Res Commun; 2023 May; 3(5):860-873. PubMed ID: 37377896
[TBL] [Abstract][Full Text] [Related]
6. CSPG4: a prototype oncoantigen for translational immunotherapy studies.
Rolih V; Barutello G; Iussich S; De Maria R; Quaglino E; Buracco P; Cavallo F; Riccardo F
J Transl Med; 2017 Jul; 15(1):151. PubMed ID: 28668095
[TBL] [Abstract][Full Text] [Related]
7. Mouse models for immuno-oncology.
Bosenberg M; Liu ET; Yu CI; Palucka K
Trends Cancer; 2023 Jul; 9(7):578-590. PubMed ID: 37087398
[TBL] [Abstract][Full Text] [Related]
8. [Interdisciplinary meeting on experimental and translational research in head and neck cancer : 12th Symposium of the Working Group Oncology, 2nd International Symposium on Immunosuppression and Immunotherapy in Cancer].
Hoffmann TK; Brunner C; Schuler PJ
HNO; 2023 Apr; 71(4):274-275. PubMed ID: 36879121
[No Abstract] [Full Text] [Related]
9. Quality-assured research environments for translational cancer research.
Berns A
Mol Oncol; 2019 Mar; 13(3):543-548. PubMed ID: 30628170
[TBL] [Abstract][Full Text] [Related]
10. Translational oncotargets for immunotherapy: From pet dogs to humans.
Mestrinho LA; Santos RR
Adv Drug Deliv Rev; 2021 May; 172():296-313. PubMed ID: 33705879
[TBL] [Abstract][Full Text] [Related]
11. Engineering Natural Killer Cells for Cancer Immunotherapy.
Rezvani K; Rouce R; Liu E; Shpall E
Mol Ther; 2017 Aug; 25(8):1769-1781. PubMed ID: 28668320
[TBL] [Abstract][Full Text] [Related]
12. Future directions in preclinical and translational cancer neuroscience research.
Demir IE; Mota Reyes C; Alrawashdeh W; Ceyhan GO; Deborde S; Friess H; Görgülü K; Istvanffy R; Jungwirth D; Kuner R; Maryanovich M; Na'ara S; Renders S; Saloman JL; Scheff NN; Steenfadt H; Stupakov P; Thiel V; Verma D; Yilmaz BS; White RA; Wang TC; Wong RJ; Frenette PS; Gil Z; ; Davis BM
Nat Cancer; 2021 Nov; 1():1027-1031. PubMed ID: 34327335
[TBL] [Abstract][Full Text] [Related]
13. Translational cancer research - a coherent cancer research continuum.
Ringborg U
Mol Oncol; 2019 Mar; 13(3):517-520. PubMed ID: 30657250
[TBL] [Abstract][Full Text] [Related]
14. Development of humanized mouse with patient-derived xenografts for cancer immunotherapy studies: A comprehensive review.
Jin KT; Du WL; Lan HR; Liu YY; Mao CS; Du JL; Mou XZ
Cancer Sci; 2021 Jul; 112(7):2592-2606. PubMed ID: 33938090
[TBL] [Abstract][Full Text] [Related]
15. A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.
Theivanthiran B; Evans KS; DeVito NC; Plebanek M; Sturdivant M; Wachsmuth LP; Salama AK; Kang Y; Hsu D; Balko JM; Johnson DB; Starr M; Nixon AB; Holtzhausen A; Hanks BA
J Clin Invest; 2020 May; 130(5):2570-2586. PubMed ID: 32017708
[TBL] [Abstract][Full Text] [Related]
16. Contemplating autoimmunity in the Aegean islands.
Walker LS; Ziegler S; Becher B
Nat Immunol; 2016 Mar; 17(3):218-20. PubMed ID: 26882250
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Models Provide Scientific Justification and Translational Relevance for Moving Novel Therapeutics into Clinical Trials for Pediatric Cancer.
Langenau DM; Sweet-Cordero A; Wechsler-Reya R; Dyer MA
Cancer Res; 2015 Dec; 75(24):5176-5186. PubMed ID: 26627009
[TBL] [Abstract][Full Text] [Related]
18. Patient-derived preclinical models to develop immunotherapies.
Seoane J
Mol Oncol; 2023 Jul; 17(7):1169-1172. PubMed ID: 37278114
[TBL] [Abstract][Full Text] [Related]
19. Mouse Models for Cancer Immunotherapy Research.
Olson B; Li Y; Lin Y; Liu ET; Patnaik A
Cancer Discov; 2018 Nov; 8(11):1358-1365. PubMed ID: 30309862
[TBL] [Abstract][Full Text] [Related]
20. Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).
Ascierto PA; Brugarolas J; Buonaguro L; Butterfield LH; Carbone D; Daniele B; Ferris R; Fox BA; Galon J; Gridelli C; Kaufman HL; Klebanoff CA; Melero I; Nathan P; Paulos CM; Ruella M; Sullivan R; Zarour H; Puzanov I
J Immunother Cancer; 2018 Jul; 6(1):69. PubMed ID: 29996914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
